A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC

The goal of this clinical trial is to evaluate the efficacy and safety of sintilimab as adjuvant therapy in node-positive esophageal squamous cell carcinoma after radical surgery without neoadjuvant therapy. The main question it aims to answer is: • Efficacy of sintilimab as adjuvant therapy Participants will receive sintilimab 200 mg once on day 1, every 21 days(Q3W).

Trial Details

NCT ID
NCT06190639
Phase
PHASE2
Sponsor
Zhejiang Cancer Hospital
Status
RECRUITING
Cancer Type
Esophageal Cancer
Interventions
  • sintilimab
Locations (sample)
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • Signed an Informed Consent Form
  • Participant type and target disease characteristics:
  • ECOG PS 0-1
  • Histologically confirmed T1-3N+M0 thoracic esophageal squamous cell cancer (AJCC 8th)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Esophageal Cancer Trials on Trialify →